Last reviewed · How we verify

Chang-Ming Huang, Prof. — Portfolio Competitive Intelligence Brief

Chang-Ming Huang, Prof. pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Akeso · 1 shared drug class
  2. Angion Biomedica Corp · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. Beijing InnoCare Pharma Tech Co., Ltd. · 1 shared drug class
  5. Betta Pharmaceuticals Co., Ltd. · 1 shared drug class
  6. Centre Leon Berard · 1 shared drug class
  7. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
  8. AB Science · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Chang-Ming Huang, Prof.:

Cite this brief

Drug Landscape (2026). Chang-Ming Huang, Prof. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chang-ming-huang-prof. Accessed 2026-05-16.

Related